Related Experiment Video
Updated: May 23, 2025
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
Therapeutic potential of triple-negative breast cancer immune checkpoint blockers: A 21-year bibliometric analysis
Zhongli Sun1,2, Cun Liu3, Yan Yao1
1College of First Clinical Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
Background:
Triple-negative breast cancer (TNBC) is an aggressive metastatic subtype of BC that frequently develops chemoresistance. Immune checkpoint blockers (ICB) have led to breakthroughs in TNBC treatment. This study aimed to explore research trends and public interest in ICB interventions for TNBC.
Methods:
We searched the Web of Science Core Collection (WoSCC) database for publications related to ICB for TNBC from 2003 to 2024. VOSviewer, CiteSpace, and R package "bibliometrix" were used to analyze the characteristics of ICB publications in TNBC from a quantitative and qualitative perspective and to visualize the results to comprehensively present the research trends in this field.
Results:
After removing duplicates, 2698 publications were included. The New England Journal of Medicine may be the leading and influential in the field of ICB in TNBC according to data on the total number of publications, number of citations, and impact factors. Its article entitled "Atezolizumab and Nab-Paclitaxel in Advanced TNBC" is 1 of the most cited articles. Keyword analysis showed that current research hotspots in this field are tumor microenvironment, complete pathological response, neoadjuvant chemotherapy, and PARP inhibitors. Future research hotspots may include the PD-L1 inhibitor durvalumab and antibody-drug conjugates (ADC).
Conclusions:
This study revealed that ICB therapy for TNBC is a rapidly evolving and high-profile topic. Future research should focus on the optimal selection of different targets for ICB in combination with neoadjuvant chemotherapy, ADC, and poly ADP-ribose polymerase inhibitors to treat TNBC.
Insights
Immune checkpoint blockers (ICB) are revolutionizing triple-negative breast cancer (TNBC) treatment. Research trends highlight combinations with chemotherapy, antibody-drug conjugates (ADC), and PARP inhibitors for improved outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Bibliometrics
Background:
- Triple-negative breast cancer (TNBC) presents aggressive metastatic potential and frequent chemoresistance.
- Immune checkpoint blockers (ICB) have emerged as a significant advancement in TNBC treatment.
- Understanding research trends and public interest in ICB for TNBC is crucial for future therapeutic development.
Purpose of the Study:
- To explore and visualize research trends and public interest in immune checkpoint blockers (ICB) for triple-negative breast cancer (TNBC).
- To identify current and future research hotspots in the field of ICB for TNBC.
Main Methods:
- Bibliometric analysis of publications from the Web of Science Core Collection (2003-2024).
- Utilized VOSviewer, CiteSpace, and R package 'bibliometrix' for quantitative and qualitative analysis.
- Visualized research characteristics to present comprehensive trends in ICB for TNBC.
Main Results:
- 2698 publications were analyzed, indicating a rapidly evolving research landscape.
- The New England Journal of Medicine and specific articles on atezolizumab show high influence.
- Current research focuses on tumor microenvironment, pathological response, neoadjuvant chemotherapy, and PARP inhibitors.
- Future research may concentrate on PD-L1 inhibitors like durvalumab and antibody-drug conjugates (ADC).
Conclusions:
- ICB therapy for TNBC is a high-profile and rapidly advancing research area.
- Future research should investigate optimal combinations of ICB with neoadjuvant chemotherapy, ADC, and PARP inhibitors for TNBC treatment.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...